Clinical Trial Update: Neoadjuvant Gemcitabine Plus Cisplatin With or Without Durvalumab in Resectable Biliary Tract Cancer [Phase 2]

View source ↗

Summary

This Phase 2 trial evaluates neoadjuvant gemcitabine plus cisplatin, with or without durvalumab, in patients with resectable biliary tract cancers. It includes …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Neoplasms
• Cholangiocarcinoma
• Gallbladder Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• Durvalumab (durvalumab)
• Gemcitabine (Gemcitabine)

Snippet

Sponsor: Asan Medical Center | Conditions: Biliary Tract Neoplasms, Gallbladder Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING